Jacobs Levy Equity Management Inc. Purchases New Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Jacobs Levy Equity Management Inc. purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 26,900 shares of the medical equipment provider's stock, valued at approximately $2,406,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. State of New Jersey Common Pension Fund D grew its holdings in Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after purchasing an additional 115 shares during the last quarter. Bleakley Financial Group LLC grew its holdings in Lantheus by 6.1% during the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after purchasing an additional 129 shares during the last quarter. Avantax Advisory Services Inc. grew its holdings in Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after purchasing an additional 132 shares during the last quarter. Foundry Partners LLC grew its holdings in Lantheus by 4.5% during the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 133 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Truist Financial lowered their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $132.67.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock valued at $6,016,046 over the last ninety days. 1.50% of the stock is owned by company insiders.

Lantheus Trading Up 1.8%

LNTH stock traded up $1.46 during midday trading on Friday, hitting $81.24. The stock had a trading volume of 913,883 shares, compared to its average volume of 981,515. The firm has a market capitalization of $5.62 billion, a price-to-earnings ratio of 13.52 and a beta of 0.23. Lantheus Holdings, Inc. has a 52 week low of $75.00 and a 52 week high of $126.89. The stock has a 50-day simple moving average of $97.11 and a 200 day simple moving average of $93.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm's revenue for the quarter was up .8% compared to the same quarter last year. During the same period last year, the business earned $1.69 earnings per share. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.